
    
      A randomized, open-label, parallel-group pilot study, to assess the pharmacodynamic effect on
      dihydrotestosterone regulated gene expression, longitudinally and in a dose dependent manner,
      of 0.5mg or 3.5mg dutasteride administered orally once daily, for three months in men with
      symptomatic benign prostatic hyperplasia or during the period between baseline and radical
      prostatectomy in men with biopsy-proven, clinically localized prostate cancer.
    
  